Thus, GR inhibition decreases ADPC and CRPC prostate cancer cell growth and enhances the cell growth inhibitory effect of enzalutamide (Figure 4H, I, Supplementary Figure S11, S17) ((23,43,51,52). This evidence concerns the gene NR3C1 and prostate carcinoma.